Serum Crosslaps® (CTX-I) ELISA

Product Description

For determination of degradation products of C-terminal telopeptides of Type I collagen (CTX-I) in human serum or plasma. CTX-I can be used as an indicator of bone resorption status.

• Supports the management of postmenopausal osteoporosis and prediction of long-term skeletal response to anti-resorptive therapies, e.g. HRT, bisphosphonates
• Encourages patient motivation and compliance
• Allows the assessment of bone resorption in patients with metabolic bone disease, e.g. hyperparathyroidism, Paget´s disease, osteodystrophy and those receiving prolonged glucocorticoid therapy
• CTX-I is considered a reference marker for osteoporosis management as indicated by IOF, IFCC and NBHA
• Easy to perform – one step incubation
• Excellent correlation with automated methods
• Part of a complete assay panel supporting bone disease management

Results are to be used in conjunction with other clinical and laboratory data as an aid in:

• Monitoring bone resorption changes of anti-resorptive therapies (such as hormone replacement therapies (HRT) with hormones or hormone like drugs and bisphosphonate therapies) in postmenopausal women and individuals diagnosed with osteopenia
• Predicting skeletal response (Bone Mineral Density) in postmenopausal women undergoing anti resorptive therapies, such as HRT with hormones or hormone like drugs and bisphosphonate therapies